BioSpace News Archive

Obsidian Therapeutics, Inc. today announced that Bristol Myers Squibb (NYSE:BMY) has opted to extend the term of the parties’ multi-year strategic collaboration for the discovery and development of novel, regulated cell therapies that utilize Obsidian’s cytoDRiVE® technology for the controlled expression of the immune enhancer CD40L.

Jaguar Health, Inc. today announced that the company sponsored the October 26, 2022 episode of dvm360 Live!

NeuroSense Therapeutics Ltd. today announced its participation in three upcoming conferences.

Radiaction Medical, Ltd. (“Radiaction”) announced today it has received an additional 510(k) Clearance from the Food and Drug Administration (FDA) for its Radiation Shielding System, one that enables compatibility with the Siemens Artis family of fluoroscopy C-Arm machines.

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD.

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed a one-time asset sale agreement to assign certain patent rights related to methods for determining the origin of cell-free DNA to Roche Diagnostics.

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced that it has received regulatory approval of a Clinical Trial Application (CTA) from the South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial of the DYAI-100 COVID-19 Receptor Binding Domain (RBD) booster vaccine.

RSIP Vision, an experienced developer of groundbreaking AI technologies for medical imaging, today reveals preliminary results from an ongoing clinical study for the evaluation of the reconstruction of a 3D knee model from 2D X-ray images at Assuta Medical Center in Tel Aviv.

Synchron announced enrollment in the COMMAND trial has commenced at the University of Pittsburgh, Pittsburgh, PA.

Totus Medicines, a drug discovery company with the mission to make any protein druggable through its breakthrough chemical biology platform, announced yesterday the poster presentation for TOS-358 at the 34th EORTC-NCI-AACR Symposium (ENA 2022) held in Barcelona Oct 26-28, 2022.